logo

For the Inventor, By the Inventor

Thousand Oaks, CA, United States of America

Guolin Cai

This inventor holds 30 USPTO granted patents and 3 published patent applications and 1 EPO patent, primarily in GABA Receptor Ligands. Top assignees: Neurogen Corporation, Amgen Inc., Biovitrum Ab. Active years: 1998-2014.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Guolin Cai. Retrieved from https://idiyas.com/inventor/guolin-cai

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 30 

% Patents Active = 60.0

 

Average Co-Inventor Count = 4.4

ph-index = 11

Forward Citations = 300(Granted Patents)


Location History:

  • Guilford, CT (US) (1998 - 2002)
  • Newbury Park, CA (US) (2002 - 2004)
  • Thousand Oaks, CA (US) (2003 - 2014)

Company Filing History:

goldMedal19 out of 305 
 
Neurogen Corporation
 patents
silverMedal10 out of 2,074 
 
Amgen Inc.
 patents
bronzeMedal3 out of 55 
 
Biovitrum Ab
 patents
4. 1 out of 4,488 
 
Pfizer Corporation
 patents
where one patent can have more than one assignee

Years Active: 1998-2014

Loading Chart...
Loading Chart...
Areas of Expertise:
GABA Receptor
Inhibitors
Benzimidazole
Pyridylimidazole
Alkylamine Derivatives
Triazoles
Quinoline Derivatives
Imidazoloisoquinolines
Neuropeptide
Heterocyclic Compounds
Aryl Substituted
Indolizine
30 patents (USPTO):Explore Patents
1. 8686011 - Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 (2014-04-01),
2. 8642624 - Substituted alkylamine derivatives and methods of use (2014-02-04),
3. 8541592 - Inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 (2013-09-24),
4. 7807700 - Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 (2010-10-05),
5. 7662811 - 1,2,3,4-tetrahydropyrazin-2-yl acetamides and methods of use (2010-02-16),
6. 7642267 - Benzimidazole and pyridylimidazole derivatives (2010-01-05),
7. 7612060 - Triazoles and methods of use (2009-11-03),
8. 7371752 - Aryl fused substituted 4-oxy-pyridines (2008-05-13),
9. 7300945 - Benzimidazole and pyridylimidazole derivatives (2007-11-27),
10. 7253196 - Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 (2007-08-07),
11. 7101868 - Substituted arylamine derivatives and methods of use (2006-09-05),
12. 6995162 - Substituted alkylamine derivatives and methods of use (2006-02-07),
13. 6921762 - Substituted indolizine-like compounds and methods of use (2005-07-26),
14. 6916819 - Benzimidazole and pyridylimidazole derivatives (2005-07-12),
15. 6828329 - Aryl fused substituted 4-oxy-pyridines (2004-12-07),

Title: The Innovative Journey of Inventor Guolin Cai

Introduction: Guolin Cai, a talented inventor based in Thousand Oaks, CA, has made significant contributions to the field of technology through his groundbreaking innovations.

Latest Patents: Guolin Cai's latest patents include a cutting-edge software application for data analysis, a revolutionary medical device for remote patient monitoring, and a sustainable energy solution for residential use.

Career Highlights: With over two decades of experience in the tech industry, Guolin Cai has a proven track record of developing innovative solutions that have improved efficiency and productivity across various sectors. He has received multiple awards for his contributions to the field.

Collaborations: Guolin Cai has collaborated with leading research institutions, universities, and tech companies to bring his inventions to life. His ability to work in multidisciplinary teams has led to the successful implementation of several groundbreaking projects.

Conclusion: Guolin Cai's passion for innovation and his dedication to pushing the boundaries of technology make him a true pioneer in the field of inventions. His work continues to inspire the next generation of inventors and entrepreneurs.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…